In a December 2025 survey at one U.S. health system, 50 of 98 people who answered an awareness question (51%) said they knew about an American Diabetes Association statement on compounded GLP-1 medicines. The statement was approved in 2024 and published in the February 2025 issue of Diabetes Care[1] [2].
Who answered the survey?
Our compounded semaglutide safety guide covers what regulators and studies say about the products. This survey asked what health professionals knew and how they used them. Researchers sent a 14-item survey to 523 people across sites in one health system. They received 125 replies (23.9%) and analyzed 99 that met their criteria, including 53 clinicians and 46 pharmacists. Some respondents skipped questions, so each result uses the number who answered that item [1].
What respondents said about safety and access
Low confidence in comparable safety was reported by 71 of 95 respondents (74.7%). At the same time, 65 of 94 (69.1%) expressed confidence that compounded products were more affordable than commercial products. Of the 91 people who answered the practice question, 52 (57.1%) said they had not incorporated the products into their practice [1].
What the FDA and ADA say
The FDA advises using compounded drugs only when an approved drug cannot meet the patient’s medical needs. Compounded drugs do not undergo FDA premarket review for safety, effectiveness or quality [3].
The ADA statement recommends against using non-FDA-approved compounded GLP-1 products because of concerns about safety, quality and effectiveness[2]. If you have questions about a prescription, ask your clinician and pharmacist which product you would receive and why it was selected.